The research team, working in the oncology department of a specialized cancer hospital in Beijing, recruited 452 hospitalized adults with pathologically confirmed lung cancer who were actively receiving chemotherapy between August and October 2024. The choice of population was deliberate. Lung cancer remains the most commonly diagnosed malignancy worldwide, and China alone reported more than one million new cases and roughly 740,000 deaths in 2022, making it the country’s leading cause of cancer-related morbidity and mortality. Chemotherapy in lung cancer is not confined to advanced disease; it is deployed as neoadjuvant and adjuvant therapy across the disease trajectory, which means patients face repeated, recurring treatment decisions rather than a single dramatic choice at diagnosis. Each cycle brings fresh opportunities to continue, modify, or abandon a regimen, and each of those junctures demands a fresh assessment of risks, side effects, functional impact, and financial cost. Unlike some cancers where a one-time surgical decision dominates, lung cancer imposes a rolling sequence of choices on patients who are often emotionally depleted, physically weakened, and cognitively taxed by rapid disease progression.

To quantify readiness, the researchers employed the Chinese version of the Preparation for Decision Making Scale, a ten-item instrument originally developed by Canadian nursing scholars and later revised by Bennett and colleagues, psychometrically validated in Chinese by Li Yu. Items are rated on a five-point Likert scale, and the total score, obtained by multiplying the summed item scores by four, ranges from 20 to 100, with higher values indicating greater readiness. In the current sample the scale demonstrated strong internal consistency, with a Cronbach’s alpha of 0.903. The median readiness score among the 452 participants was 62.00, with an interquartile range of 56.00 to 70.00, which the authors characterize as a moderate overall level. In practical terms, this means that the typical patient in the study reported being reasonably but not robustly prepared to engage in treatment decision-making, leaving substantial room for improvement in a population where inadequate decision preparation has previously been linked to higher decisional conflict, lower satisfaction, and poorer treatment adherence.

The study’s analytical backbone was a hierarchical multiple linear regression grounded in the Common Sense Model of Self-Regulation, a classic theoretical framework in health psychology that describes how individuals confronting a health threat form cognitive and emotional representations of the illness, adopt coping behaviors in response, and then evaluate outcomes. The researchers mapped this framework onto the decision-making context: the cognitive stage was captured by measures of decision-making attitude, decisional conflict, and decisional regret, while the coping outcome was embodied in the overall level of decision-making readiness. Attitude was measured with the Chinese version of the Patient Attitude Toward Treatment Decision-Making Scale, a twelve-item instrument developed by Sainio and colleagues and validated in Chinese by Ma Lili. Decisional conflict was assessed with the sixteen-item Decisional Conflict Scale developed by O’Connor, which spans three dimensions—clarity of information and values, perceived decision support and effectiveness, and decisional uncertainty—with scores above 25 indicating the presence of conflict and scores above 37.5 suggesting possible decision delay. Decisional regret was measured with the five-item Decision Regret Scale of Brehaut and colleagues, although its internal consistency in this sample was low, with a Cronbach’s alpha of 0.401, and the authors caution that regret-related findings should be interpreted with appropriate restraint.

The statistical results were striking in their proportions. In the first block of the regression, sociodemographic and clinical contextual variables—factors such as economic status and residential location—explained 9.2 percent of the total variance in decision-making readiness. When the psychological variables of decisional conflict and participation attitude were added in the second block, the explanatory power jumped to 31.1 percent, more than tripling the variance accounted for. Four factors emerged as significant independent predictors: economic status, residential location, decisional conflict, and decision participation attitude. Correlation analysis reinforced the pattern, showing that readiness was positively associated with patients’ willingness to participate in treatment decisions and negatively associated with decisional conflict. Collinearity diagnostics confirmed that the psychological predictors were not redundant, with variance inflation factors ranging from 1.197 to 1.409, well below conventional thresholds of concern. In plain language, the study found that how a patient feels about deciding matters far more than who the patient is.

This asymmetry between demographic and psychosocial predictors is arguably the study’s most consequential message. Economic status and residential location, while statistically significant, are largely fixed or slowly changing features of a patient’s life that clinicians cannot readily modify at the bedside. Decisional conflict and participation attitude, by contrast, are psychological states that can be assessed, monitored, and targeted with structured interventions. Decision aids, teach-back communication techniques, question prompt lists, and dedicated nursing decision-support consultations are all evidence-informed tools designed to reduce uncertainty, clarify values, and bolster confidence. The finding that these modifiable variables explain a substantial share of readiness variance offers a concrete roadmap: screening patients for decisional conflict at admission could identify those at greatest risk of unprepared decision-making, and tailored support could then be deployed before critical treatment junctures arrive.

The study also fills a notable gap in the oncology literature. Prior research on treatment decision-making in cancer has concentrated heavily on negative indicators—decisional conflict, decisional regret, and dissatisfaction with the decision process—while giving comparatively little attention to decision-making readiness as an independent, positive, adaptive psychological construct. Readiness, as the authors define it, encompasses the comprehensive preparedness of an individual in knowledge, attitude, ability, and environmental support when facing a decision situation, enabling effective participation and informed choice. Moreover, much of the existing work has been descriptive, lacking an organizing theoretical framework to explain how readiness forms. By anchoring the analysis in the Common Sense Model of Self-Regulation and demonstrating that the model’s cognitive and coping stages map coherently onto measurable decision-related variables, the researchers provide both empirical data and a theoretical scaffold that future intervention studies can build upon. The authors note that their findings support the applicability of the Common Sense Model in the field of cancer treatment decision-making research more broadly.

The clinical context adds urgency to these numbers. A traditionally paternalistic approach in thoracic oncology has been recognized as a barrier to shared decision-making, and patients whose decisions are made entirely by family members—still a common practice in some health systems—were excluded from this study precisely to focus on those expected to participate themselves. Even among this engaged cohort, readiness was only moderate. The authors point out that lung cancer patients may face greater decisional complexity than patients with many other cancer types, driven by rapid disease progression, high emotional distress at the time of diagnosis, and limited time to absorb and process information. When the window between diagnosis and a consequential treatment choice is measured in days rather than weeks, the quality of decision support delivered in that window becomes decisive, and a patient who enters it with unresolved internal conflict and a passive attitude toward participation is at a measurable disadvantage.

Methodologically, the study was carefully sized and executed. Following the rule that no fewer than ten participants are required per predictor variable, twenty-five candidate predictors demanded a minimum of 250 participants; anticipating a 20 percent invalid-questionnaire rate raised the floor to 313, and the final sample of 452 comfortably exceeded it. Data were collected through structured electronic questionnaires administered by trained research nurses, with each device permitted a single submission, standardized instructions for every section, and an average completion time of approximately fifteen minutes. Patients with psychiatric histories or severe cognitive impairment, those too ill to continue chemotherapy, and those unaware of their diagnosis were excluded. Analyses were conducted in SPSS version 26.0, with Shapiro-Wilk tests for normality, appropriate parametric and non-parametric comparisons, and two-tailed significance testing throughout. The researchers are transparent about the design’s cross-sectional nature, which captures association rather than causation, and about convenience sampling at a single specialized hospital, which may limit generalizability to community settings or to patients managed outside major urban cancer centers.

Even with those caveats, the implications for nursing practice and oncology care are difficult to ignore. The authors conclude that targeted nursing decision-support interventions are urgently needed to assess and elevate decision-making readiness among lung cancer patients receiving chemotherapy, as a pathway toward genuinely patient-centered treatment decision-making. The idea that readiness can be measured with a short, reliable, validated scale—and that its principal modifiable determinants are conflict and attitude rather than age, education, or disease stage—transforms an abstract ideal of shared decision-making into an operational clinical target. As oncology systems worldwide push toward greater patient involvement, this study suggests the critical question is not simply whether patients are invited to the table, but whether, when they arrive, they arrive prepared.

Shared decision-making is a practice that encourages collaboration between patients and healthcare providers, allowing for a multidimensional approach to treatment. This proactive engagement can enhance patient satisfaction, promote better adherence to therapies, and ultimately lead to improved survival rates. The recent study highlights the dynamics within the Bangladeshi healthcare system, where the interplay of cultural, economic, and logistical factors necessitates innovative strategies to empower patients.

In Bangladesh, cancer continues to be a leading cause of morbidity and mortality. Despite advancements in treatment modalities, many patients face barriers to accessing high-quality care. The scarcity of resources, including trained healthcare personnel and medical facilities, accentuates the need for a framework that not only addresses treatment options but also facilitates patient participation in health decisions. This research underscores the importance of a paradigm shift from a paternalistic model of care to one that emphasizes shared responsibility.

According to the study conducted by Shahjalal and colleagues, effective communication emerges as a cornerstone of shared decision-making. The researchers emphasize that clear conversations regarding treatment options, risks, and benefits are vital in establishing trust between healthcare providers and patients. This communication fosters an environment where patients feel valued and empowered to express their preferences. Such a shift can significantly reduce anxiety and improve the overall treatment experience.

The research observed various demographic factors that influence shared decision-making. Age, education, and socioeconomic status were noted as critical elements that affect how patients engage in the decision-making process. For example, younger patients with higher educational attainment were more likely to participate actively in discussions about their treatment options. This observation points to the need for targeted educational initiatives that can enhance the decision-making skills of diverse patient populations, ensuring inclusivity across all strata of society.

Additionally, the study explored the technological advancements that can facilitate shared decision-making in Bangladesh. Digital health tools and telemedicine have gained traction, especially in settings where face-to-face consultations may be limited. By integrating technology into the healthcare framework, patients can access information regarding their treatment options and side effects readily, enabling them to make informed decisions in consultation with their healthcare teams. Such initiatives could bridge the gap caused by physical distances and resource shortages.

The researchers also highlighted the importance of incorporating cultural and social dynamics into shared decision-making processes. Understanding a patient’s cultural background can significantly impact their perspective on health and illness. In Bangladesh, where cultural norms may dictate patient autonomy differently, healthcare providers are challenged to respect these beliefs while fostering a scenario where shared decision-making can thrive. Training programs focused on cultural competency for healthcare providers can help facilitate these crucial conversations.

Economic considerations play an essential role in cancer care, particularly in a resource-limited country like Bangladesh. The research discusses how economic constraints can affect the options available to patients, thereby influencing their engagement in decision-making. When treatment options are limited due to cost considerations, patients may feel disenfranchised, believing they have little to no say in their care. Here, the role of advocacy groups becomes vital in educating patients about their rights and the importance of participation in their treatment plans.

The study also suggests that involving family members in the decision-making process can create a supportive environment for patients. Family dynamics are integral to healthcare decisions in many cultures, including Bangladesh. When patients feel supported by their loved ones, they are more likely to voice their preferences and concerns during consultations with their healthcare providers. This collaboration can lead to decisions that resonate positively with both the patient and their family, fostering a more holistic approach to cancer care.

Furthermore, by documenting patient preferences and outcomes within clinical settings, healthcare systems can facilitate feedback loops that inform future practices. This type of data collection is crucial for evaluating the effectiveness of shared decision-making initiatives and identifying areas for improvement. As the study points out, incorporating patient feedback into treatment pathways can contribute to a continuous quality improvement cycle in oncology care.

The implications of this research extend beyond the confines of Bangladesh. Global stakeholders in healthcare can draw valuable lessons on the importance of shared decision-making in cancer care. The study presents a compelling case for the necessity of adapting healthcare models to encourage patient engagement, particularly in low- and middle-income countries where resources may be limited but patient needs are paramount.

In conclusion, the findings from the research conducted by Shahjalal and colleagues serve as a clarion call for the integration of shared decision-making in cancer care across the globe. By promoting patient engagement, respecting cultural contexts, and utilizing technological advancements, healthcare systems can create an environment that is conducive to improved patient outcomes. The journey towards equitable and effective cancer care is ongoing, but the evidence suggests that empowering patients through shared decision-making represents a critical step forward.

As we reflect on these crucial developments in Bangladesh’s healthcare landscape, it becomes evident that ongoing research and discourse around shared decision-making can lead to more inclusive and patient-centered approaches in cancer treatment. This approach is not merely an abstract ideal but a tangible pathway to transforming the patient experience and health outcomes in oncology in resource-constrained settings.

Subject of Research: Shared Decision-Making in Cancer Care

Article Title: Shared decision-making in cancer care in Bangladesh: evidence from a resource-constrained setting

Article References:

Shahjalal, M., Doshi, R.H., Garg, S.K. et al. Shared decision-making in cancer care in Bangladesh: evidence from a resource-constrained setting.
J Cancer Res Clin Oncol 151, 310 (2025). https://doi.org/10.1007/s00432-025-06362-z

Image Credits: AI Generated

DOI: 10.1007/s00432-025-06362-z

Keywords: Shared decision-making, cancer care, Bangladesh, resource-constrained setting, patient engagement, healthcare communication, cultural competency, technology in healthcare, economic factors in healthcare.

This groundbreaking research, spearheaded by clinician-researchers at the UCLA Health Jonsson Comprehensive Cancer Center and the UCLA Palliative Care Research Center, sheds new light on the psychosocial dimensions of cancer care. Published recently in the prestigious journal Cancer, the study exposes that a substantial proportion of patients with advanced cancer who prefer symptom relief and comfort-oriented care perceive their medical treatment as primarily focused on life prolongation instead. This divergence accentuates the challenge of aligning clinical interventions with patients’ values and goals, a fundamental tenet of patient-centered oncology.

The investigators conducted a sophisticated post-hoc cross-sectional analysis leveraging baseline data from a multi-site clinical trial centered around advance care planning among diverse seriously ill patient populations. This rigorous analytical approach enabled comparison of responses from 1,100 patients, 231 of whom had advanced cancer, alongside individuals with other life-limiting illnesses including advanced heart failure, chronic obstructive pulmonary disease (COPD), end-stage renal disease, and end-stage liver disease. Such comparative insights are critical for disentangling disease-specific patterns in treatment goal discordance.

Intriguingly, the data reveal that approximately 37% of advanced cancer patients who favored comfort-centered care reported that their actual treatment emphasis was on extending life. In contrast, only about 19% of patients with other serious chronic conditions experienced this type of misalignment. These findings suggest a uniquely pronounced gap in goal-concordant care within the oncology realm, despite similar severity and mortality risk profiles across the diverse patient groups studied. The implications challenge existing assumptions that oncology teams consistently calibrate treatment plans to patient preferences.

Further analysis demonstrates that the overall preferences between cancer and non-cancer patient cohorts are broadly comparable: roughly one quarter desire life-extending interventions, whereas close to half prefer care focused on symptom management and comfort. Yet, the realized care many patients perceive diverges substantially. More than half of patients with advanced cancer perceive their care as life-prolonging, while a smaller proportion—just 19%—report receiving comfort-oriented treatment, compared with 28% in the non-cancer cohort. This discordance highlights potential systemic issues in delivering palliative and supportive care that respects patient autonomy.

The study also elucidates the complex interplay of patient age, baseline health status, and treatment aggressiveness. Younger advanced cancer patients, typically with better functional reserves, may be offered and accept more aggressive therapies, even when these options do not align neatly with stated care goals. Additionally, advances in oncology therapeutics blur the distinction between life prolongation and quality of life benefits, complicating shared decision-making processes. These nuances demand nuanced, ongoing communication strategies.

Dr. Manan Shah, the study’s lead author and a clinical instructor in hematology/oncology at UCLA, underscores the urgency of addressing this treatment-goal discordance. He emphasizes that while some divergence is understandable due to the inherent complexity of serious illness management, the high prevalence of misaligned care perceptions among cancer patients is both surprising and concerning. It signals a critical need to enhance the depth and quality of communication between clinicians and patients to ensure that treatment trajectories genuinely reflect patient values.

Complementing these insights, senior author Dr. Anne Walling, a professor of medicine at UCLA, elaborates on the intricate decision-making landscape in advanced cancer. She notes that novel cancer therapies often offer the dual promises of extending survival and ameliorating symptom burden, yet these benefits may come with trade-offs. High-quality communication is essential to convey these complexities effectively, allowing patients to make informed choices aligned with their personal goals and quality of life priorities.

The findings also carry significant implications for prognosis awareness and advance care planning. The research team advocates for oncology care teams to proactively engage patients early in their treatment journey in candid discussions about prognosis, treatment intents, and personal priorities. This iterative, patient-centered approach is vital to reconcile expectations and optimize therapeutic plans congruent with individual goals.

Of particular note, the study reports no significant difference in two-year survival rates comparing patients who perceived their care as life-extending versus those who viewed it as comfort-centered (24% versus 15% mortality, respectively). This outcome challenges the assumption that aggressive life-prolonging treatments unequivocally yield meaningful survival benefits and further highlights the importance of aligning care with quality-of-life considerations.

The research also raises a call to action for clinicians to nurture an environment where patients feel empowered to voice concerns when their care does not match their preferences. Dr. Shah stresses that physicians must be responsive and willing to recalibrate treatment strategies in accordance with patients’ evolving goals. Such dynamic communication and shared decision-making practices possess the transformative potential to enhance patient satisfaction and clinical outcomes.

Contributing to the robust multidisciplinary team behind this important study were noted experts including Neil Wenger, John Glaspy, Ron Hays, and Chi-Hong Tseng from UCLA, as well as Rebecca Sudore and colleagues from the University of California system. Their collaborative efforts elucidate critical gaps and opportunities in delivering compassionate, goal-concordant care in advanced illness.

In a broader context, these findings underscore systemic challenges that persist in integrating palliative care principles into oncology. Despite growing recognition of the importance of patient-centered outcomes and quality of life, the oncology community must intensify efforts to embed nuanced communication frameworks and shared-decision models within everyday clinical practice. Addressing these gaps is essential to fulfill the ethical imperative of honoring patient autonomy amid the complexity of advanced cancer care.

As oncology care continues to evolve with scientific advances, ensuring that treatment aligns with patient values must remain a paramount focus. This pivotal study not only illuminates a critical area of unmet need but also charts a path forward: fostering deeper, transparent, and ongoing dialogues that center on the unique goals and preferences of each patient. Only through such commitment can the promise of truly personalized cancer care be realized.

Subject of Research: Alignment of treatment goals with patient care preferences in advanced cancer patients.

Article Title: [Not specified in the provided content.]

News Publication Date: [Not specified in the provided content.]

Web References:

• UCLA Health Jonsson Comprehensive Cancer Center: https://www.uclahealth.org/cancer
• UCLA Palliative Care Research Center: https://www.uclahealth.org/departments/medicine/internal-medicine/research/research-programs/palliative-care-research-center
• Journal article DOI: http://dx.doi.org/10.1002/cncr.35976

References:

• Shah M. et al., “Treatment Goal Concordance in Advanced Cancer: A Cross-sectional Analysis,” Cancer, DOI: 10.1002/cncr.35976

Image Credits: [Not specified in the provided content.]

Keywords: Cancer research; Patient-centered care; Advanced cancer; Treatment goals; Palliative care; Communication in oncology; Shared decision-making.

The study employed an adapted version of the Control Preferences Scale to delineate the roles patients prefer to adopt during consultations and the roles they actually experience. This instrument categorizes decision-making involvement into patient-led, shared, or doctor-led roles. By engaging 1264 cancer patients across multiple clinical sites, the research team captured a comprehensive portrait of decision-making dynamics across various cancer types, enabling granular analysis of how preferences correlate with on-the-ground realities.

Notably, the data revealed a nuanced pattern in patient engagement. Roughly 44% of respondents expressed a preference for taking the lead in decisions about their treatment, while 40% favored a collaborative or shared decision-making model alongside their doctors, and a minority, approximately 16%, preferred to defer decisional authority to their physicians. Intriguingly, respondents reported even higher actual engagement levels in patient-led decision-making, with over 56% experiencing autonomy in their treatment choices, suggesting a somewhat proactive healthcare environment or possibly a mismatch in patient perceptions.

The concordance between what patients wanted and what they experienced was categorized as moderate, with a kappa coefficient of 0.41. This statistic indicates that, although there is some alignment between preferred and achieved decision-making roles, a significant portion of patients encountered discrepancies. Such findings underscore ongoing gaps in communication and support, where patients’ desires for involvement are not fully realized or recognized during clinical interactions.

Family involvement emerged as a major theme, aligning with prevalent cultural paradigms in China where families often serve as fiduciaries and emotional pillars in the patient journey. Over three-quarters of patients preferred shared decision-making involving family members, and nearly 71% reported experiencing this collaborative approach. This congruence emphasizes the critical role families play as mediators, advocates, and co-decision-makers, challenging the simplistic Western binary of patient autonomy versus physician paternalism.

Cancer type further stratified patients’ experiences and preferences. Breast cancer patients demonstrated a statistically significant tendency to adopt more passive roles in decision-making. This passivity, potentially reflective of demographic variables such as gender norms or disease-specific psychosocial factors, points to complex interrelations between illness identity and agency. Conversely, uterine cancer patients often experienced less active decision-making roles than they preferred, highlighting a discrepancy that could negatively impact treatment satisfaction and psychological outcomes.

The research’s cross-sectional design, spanning multiple clinical sites, lends robustness and generalizability to the findings, revealing systemic patterns rather than isolated practices. It signals a need for clinicians to cultivate bespoke communication strategies that acknowledge varying patient desires and familial dynamics. Emphasizing the triadic relationship between patient, physician, and family members stands to enhance care quality and align treatment planning with individual values.

This study also prompts reflection on the cultural underpinnings shaping decision-making. Unlike Western models that often prioritize individual autonomy, Chinese healthcare incorporates Confucian values promoting family cohesion and collective responsibility. Such cultural nuances necessitate adaptive frameworks in patient engagement that transcend generic shared decision-making models and instead respect cultural context, balancing individual preferences with family input.

From a methodological standpoint, the use of multivariate logistic regression allowed the researchers to control for confounding variables such as cancer type and family involvement, clarifying their distinct impacts on decision-making congruence. This analytical rigor strengthens the causal inferences and supports targeted interventions aimed at improving patient-centered care within oncology.

Clinicians and healthcare policymakers should interpret these findings as an impetus to refine decision-making protocols, ensuring they accommodate patients’ desires to participate actively or collaboratively in their cancer treatment plans. For populations like uterine cancer patients, special attention must be paid to bridging gaps between expected and actual involvement, perhaps through enhanced counseling or decision aids.

Furthermore, the high prevalence of shared decision-making involving families raises ethical considerations regarding confidentiality, consent, and patient autonomy. Structured communication pathways that include families while safeguarding patient rights must be developed and integrated into oncology practice guidelines.

This pioneering study from China enriches the global dialogue about patient empowerment in oncology by illuminating the complex, culturally embedded realities patients face. It advocates for nuanced, culturally sensitive approaches that reconcile medical expertise, patient will, and familial influence, ultimately striving to optimize treatment outcomes and patient satisfaction.

The implications extend beyond China, serving as a call to international oncology communities to reevaluate and personalize decision-making frameworks in diverse sociocultural milieus. Embracing such complexity is critical as the oncology field moves toward precision medicine not only in biology but also in communication and care delivery.

To conclude, this research underscores that while the aspiration for patient-centered decision-making is widely embraced, the pathways to its realization are multifaceted, culturally contingent, and necessitate ongoing attention. By understanding the divergences and congruences between cancer patients’ preferred and experienced decision roles across different cancers and cultural settings, healthcare providers can catalyze a transformative shift toward truly participatory oncology care.

Subject of Research: Cancer patients’ preferred and experienced decision-making roles in collaboration with doctors and family members in China.

Article Title: Congruence of cancer patients’ desired and achieved decision-making roles between self, doctor and family: a cross-sectional multi-site survey.

Article References:
Wang, D., Yan, S., Fan, M. et al. Congruence of cancer patients’ desired and achieved decision-making roles between self, doctor and family: a cross-sectional multi-site survey. BMC Cancer 25, 1120 (2025). https://doi.org/10.1186/s12885-025-14510-4

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14510-4